Enhancing Glycemic Control in T2DM: Achieving Standards of Care in Primary Care: Case 1: Applying Evidence-based Guidelines to Reduce Microvascular and Macrovascular Risk

Program Description:

Achieving and maintaining target AIC levels challenges both patients with diabetes and the primary care clinicians who provide care for them. This three-part case clinic series, “Enhancing Glycemic Control in Type 2 Diabetes: Achieving Standards of Care in Primary Care,” presents common, real-world problems in diabetes management and how to respond to them. This case reviews how current treatment strategies for a 42-year-old woman could be modified to help her reach her so-far elusive goal of an A1C below 7% and thereby limit or delay complications of diabetes.

INTENDED AUDIENCE:

Primary Care Physicians, Nurse Practitioners, Physician Assistants

Activity Objectives:

After taking part in this educational activity, participants should be better able to:

• Describe the interrelated pathophysiologic abnormalities that contribute to progressive beta‐cell failure and to the clinical manifestations and complications of T2DM


• Apply current evidence‐based guidelines and expert recommendations for modifying and advancing therapy when glycemic goals for T2DM have not been met


• Identify potential barriers to effective self‐management in patients with T2DM and devise practical strategies to help address those obstacles


• Devise strategies that foster better control of glycemic patterns, particularly postprandial glucose levels, in people with T2DM

Faculty:

Richard S. Beaser, MD (Course Director/Chair)
Medical Executive Director
Professional Education
Joslin Diabetes Center
Associate Clinical Professor of Medicine
Harvard Medical School
Boston, MA

Seth N. Braunstein, MD, PhD
Associate Professor of Medicine
Hospital of the University of Pennsylvania
Philadelphia, PA

Patricia Bonsignore, RN, CDE, MS
Manager, Clinical Education Programs, HCS
Joslin Diabetes Center
Boston, MA

Robert E. Heinig, MD
Chief of Endocrinology/Metabolism
Rochester General Hospital
Clinical Professor of Medicine
University of Rochester School of Medicine
Rochester, NY

Disclosures:

Faculty
Richard S. Beaser, MD, has no relevant relationships to disclose.

Seth N. Braunstein, MD, PhD, has no relevant relationships to disclose.

Patricia Bonsignore, RN, CDE, MS, has no relevant relationships to disclose.

Robert E. Heinig, MD, has received grants/research support from CV Therapeutics, Inc., Novartis, AstraZeneca, and Daiichi Sankyo, Inc., and consulting fees from CV Therapeutics, Inc., AstraZeneca, and Merck & Co., Inc.


Publishing Staff Disclosures
Jill Rovitzky Black, Melissa Johnson, and Anne Bardsley, Haymarket Medical Education, have nothing to disclose with regard to commercial support.

Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. The Joslin Diabetes Center, Lilly USA, LLC, and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Joslin Diabetes Center, Lilly USA, LLC, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accredited Provider:

This program is sponsored by the Joslin Diabetes Center.

Produced by:

Commercial Supporter:

Supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Instructions:

To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.